| Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors VA Adalsteinsson, G Ha, SS Freeman, AD Choudhury, DG Stover, ... Nature communications 8 (1), 1324, 2017 | 742 | 2017 |
| Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer JG Lohr, VA Adalsteinsson, K Cibulskis, AD Choudhury, M Rosenberg, ... Nature biotechnology 32 (5), 479-484, 2014 | 603 | 2014 |
| Lack of PTEN sequesters CHK1 and initiates genetic instability J Puc, M Keniry, HS Li, TK Pandita, AD Choudhury, L Memeo, ... Cancer cell 7 (2), 193-204, 2005 | 408 | 2005 |
| Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing SR Viswanathan, G Ha, AM Hoff, JA Wala, J Carrot-Zhang, CW Whelan, ... Cell 174 (2), 433-447. e19, 2018 | 320 | 2018 |
| Coordination of an array of signaling proteins through homo-and heteromeric interactions between PDZ domains and target proteins XZS Xu, A Choudhury, X Li, C Montell The Journal of cell biology 142 (2), 545-555, 1998 | 279 | 1998 |
| Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer AA Hamid, KP Gray, G Shaw, LE MacConaill, C Evan, B Bernard, M Loda, ... European urology 76 (1), 89-97, 2019 | 205 | 2019 |
| Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer DG Stover, HA Parsons, G Ha, SS Freeman, WT Barry, H Guo, ... Journal of Clinical Oncology 36 (6), 543, 2018 | 205 | 2018 |
| Ubiquitination and proteasomal degradation of the BRCA1 tumor suppressor is regulated during cell cycle progression AD Choudhury, H Xu, R Baer Journal of Biological Chemistry 279 (32), 33909-33918, 2004 | 143 | 2004 |
| Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions ML Cheng, E Pectasides, GJ Hanna, HA Parsons, AD Choudhury, ... CA: a cancer journal for clinicians 71 (2), 176-190, 2021 | 138 | 2021 |
| EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer KL Morel, AV Sheahan, DL Burkhart, SC Baca, N Boufaied, Y Liu, X Qiu, ... Nature cancer 2 (4), 444-456, 2021 | 137 | 2021 |
| The role of genetic markers in the management of prostate cancer AD Choudhury, R Eeles, SJ Freedland, WB Isaacs, MM Pomerantz, ... European urology 62 (4), 577-587, 2012 | 133 | 2012 |
| Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer HA Parsons, J Rhoades, SC Reed, G Gydush, P Ram, P Exman, K Xiong, ... Clinical Cancer Research 26 (11), 2556-2564, 2020 | 131 | 2020 |
| Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features BA McGregor, RR McKay, DA Braun, L Werner, K Gray, A Flaifel, ... Journal of Clinical Oncology 38 (1), 63, 2020 | 125 | 2020 |
| Tumor fraction in cell-free DNA as a biomarker in prostate cancer AD Choudhury, L Werner, E Francini, XX Wei, G Ha, SS Freeman, ... JCI insight 3 (21), 2018 | 112 | 2018 |
| ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer S Rafiei, K Fitzpatrick, D Liu, MY Cai, HA Elmarakeby, J Park, C Ricker, ... Cancer research 80 (11), 2094-2100, 2020 | 88 | 2020 |
| Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies BA McGregor, MT Campbell, W Xie, S Farah, MA Bilen, AL Schmidt, ... Cancer 127 (6), 840-849, 2021 | 66 | 2021 |
| A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma AH Nassar, KW Mouw, O Jegede, AB Shinagare, J Kim, CJ Liu, ... British journal of cancer 122 (4), 555-563, 2020 | 66 | 2020 |
| Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits X Yao, AD Choudhury, YJ Yamanaka, VA Adalsteinsson, TM Gierahn, ... Integrative biology 6 (4), 388-398, 2014 | 52 | 2014 |
| CREB5 promotes resistance to androgen-receptor antagonists and androgen deprivation in prostate cancer JH Hwang, JH Seo, ML Beshiri, S Wankowicz, D Liu, A Cheung, J Li, ... Cell reports 29 (8), 2355-2370. e6, 2019 | 51 | 2019 |
| Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer RR McKay, W Xie, H Ye, FM Fennessy, Z Zhang, R Lis, C Calagua, ... The Journal of urology 206 (1), 80-87, 2021 | 47 | 2021 |
